HOME > OUR WORLD > ABOUT US > CORPORATE OVERVIEW

CORPORATE OVERVIEW

AN INNOVATION LED TRANSNATIONAL PHARMACEUTICAL COMPANY

HEADQUARTERED IN MUMBAI, INDIA, LUPIN LIMITED TODAY IS AN INNOVATION LED TRANSNATIONAL PHARMACEUTICAL COMPANY PRODUCING A WIDE RANGE OF QUALITY, AFFORDABLE GENERIC AND BRANDED FORMULATIONS AND APIs FOR THE DEVELOPED AND DEVELOPING MARKETS OF THE WORLD.

Dr. Desh Bandhu Gupta's vision and dream to fight life threatening infectious diseases and to manufacture drugs of the highest social priority led to the formation of Lupin in the year 1968. His Vision, his inimitable commitment and verve have steered Lupin to achieving the distinction of becoming one of the fastest growing Generic pharmaceutical companies globally. Lupin first gained recognition when it became one of the world's largest manufacturers of Tuberculosis drugs. The Company today has significant market share in key markets in the Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy segments, not to mention global leadership positions in the Anti-TB and Cephalosporins segments. segments.

The Company's R&D endeavours have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals. Lupin's world class manufacturing facilities, spread across India and Japan, have played a critical role in enabling the companies realize its global aspirations. Benchmarked to International standards, these facilities are approved by international regulatory agencies like US FDA, UK MHRA, Japan's MHLW, TGA Australia, WHO, and the MCC South Africa. Our Drugs and products reach over 100 countries in the world.

Lupin is the 7th and the 6th largest generics pharmaceutical company by market capitalization (June 30th, 2017, Bloomberg) and total revenue (March 31st, 2017, Bloomberg). The Company is the 4th largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT March 2017); the 2nd largest Indian pharmaceutical company by total revenue (March 31st, 2017, Bloomberg); the 6th largest generic pharmaceutical player in Japan (Quintiles IMS MAT June 2017). and the 6th largest company in Indian Pharmaceutical Market (Quintiles IMS MAT June 2017).” For the financial year ended 31st March, 2017, Lupin’s Consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively.

"Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation"

Dr. Desh Bandhu Gupta

Founder and Chairman
download financial highlights